Gastroenterology
Volume 133, Issue 5 , Pages 1445-1451 , November 2007

Low Resistance to Adefovir Combined With Lamivudine: A 3-Year Study of 145 Lamivudine-Resistant Hepatitis B Patients

  • Pietro Lampertico

      Affiliations

    • “A. M. and A. Migliavacca” Center for Liver Disease, Division of Gastroenterology, Department of Medicine, Fondazione Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    • ,
  • Mauro Viganò

      Affiliations

    • “A. M. and A. Migliavacca” Center for Liver Disease, Division of Gastroenterology, Department of Medicine, Fondazione Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    • ,
  • Elena Manenti

      Affiliations

    • “A. M. and A. Migliavacca” Center for Liver Disease, Division of Gastroenterology, Department of Medicine, Fondazione Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    • ,
  • Massimo Iavarone

      Affiliations

    • “A. M. and A. Migliavacca” Center for Liver Disease, Division of Gastroenterology, Department of Medicine, Fondazione Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    • ,
  • Erwin Sablon

      Affiliations

    • Infectious Disease Unit, Innogenetics NV, Ghent, Belgium
    • ,
  • Massimo Colombo

      Affiliations

    • “A. M. and A. Migliavacca” Center for Liver Disease, Division of Gastroenterology, Department of Medicine, Fondazione Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    • Corresponding Author InformationAddress requests for reprints to: Massimo Colombo, MD, 1st Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Policlinico, Mangiagallii, Regina Elena, University of Milan, Via F. Sforza 35 - 20122 Milan, Italy. fax: (39) 0250320410.

Received 18 April 2007 ,Accepted 29 August 2007.

References 

  1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–539
  2. Marcellin P, Chang TT, Lim SG, et al. Adefovir Dipivoxil 437 Study Group Adefovir dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis B. N Engl J Med. 2003;348:806–814
  3. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir Dipivoxil 438 Study Group Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743–1751
  4. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004;126:81–91
  5. Peters MG, Hann HW, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2004;126:91–101
  6. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen–negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology. 2005;42:121–129
  7. Lampertico P, Viganò M, Manenti E, et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology. 2005;42:1414–1419
  8. Liaw YF, Lee CM, Chien RN, et al. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis. J Viral Hepat. 2006;13:250–255
  9. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol. 2006;44:283–290
  10. Yeon JE, Yoo W, Hong SP, et al. Resistance to adefovir dipivoxil (ADV) in lamivudine resistant chronic hepatitis B patients treated with ADV. Gut. 2006;55:1488–1495
  11. Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology. 2006;43:1385–1391
  12. Chen CH, Wang JH, Lee CM, et al. Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. Antiviral Ther. 2006;11:771–778
  13. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl. 2007;13:349–360
  14. Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol. 2006;44:422–431
  15. Zoulim F. In vitro models for studying hepatitis B virus drug resistance. Semin Liver Dis. 2006;26:171–180
  16. Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol. 2006;44:62–67
  17. Hussain M, Fung S, Libbrecht E, et al. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol. 2006;44:1094–1097
  18. Doutreloigne J, Van Assche E, Sablon E. Analysis of drug resistance mutations associated with entecavir, tenofovir and adefovir dipivoxil treatment with a novel line probe assay (LiPA). (abstr) J Hepatol. 2007;46:S196
  19. Schildgen O, Sirma H, Funk A, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med. 2006;354:1807–1812
  20. Curtis M, Zhu Y, Borroto-Esoda K. HBV rtI233V polymerase variant remains sensitive to adefovir. (abstr) J Hepatol. 2007;46:S26
  21. Villet S, Pichoud C, Villeneuve JP, et al. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology. 2006;131:1253–1261
  22. Liaw YF, Sung JJY, Chow WC, et al. Cirrhosis Asian Lamivudine Multicentre Study Group Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531
  23. Di Marco V, Marzano A, Lampertico P, et al. Italian Association for the Study of the Liver (AISF) Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology. 2004;40:883–891
  24. van Bömmel F, Zöllner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV-DNA level during adefovir therapy. Hepatology. 2006;44:318–325
  25. Hezode C, Chevaliez S, Bouvier-Alias M, et al. Efficacy and safety of adefovir dipivoxil 20mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. J Hepatol. 2007;46:791–796
  26. Rapti I, Dimou E, Mitsoula P, et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology. 2007;45:307–313

 Supported in part by Consorzio Interuniversitario Trapianti d’Organo, Rome, and FIRST 2006, University of Milan.

 The authors report no conflict of interest.

PII: S0016-5085(07)01640-X

doi: 10.1053/j.gastro.2007.08.079

Gastroenterology
Volume 133, Issue 5 , Pages 1445-1451 , November 2007

Article Tools

* Image Usage & Resolution